Provided by Tiger Trade Technology Pte. Ltd.

VolitionRX

0.3102
-0.0298-8.76%
Post-market: 0.31720.0070+2.26%18:20 EDT
Volume:1.07M
Turnover:345.79K
Market Cap:5.86M
PE:-0.08
High:0.3401
Open:0.3371
Low:0.3058
Close:0.3400
52wk High:14.80
52wk Low:0.3058
Shares:18.90M
Float Shares:17.23M
Volume Ratio:0.72
T/O Rate:6.19%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.8023
EPS(LYR):-4.3726
ROE:-730.06%
ROA:-142.94%
PB:-0.18
PE(LYR):-0.07

Loading ...

VolitionRx posts $1 million Q1 revenue, up 300% year over year

Reuters
·
May 27

VolitionRx submits peer-reviewed study of Nu.Q Vet feline lymphoma blood test, eyes $5 million milestone

Reuters
·
May 27

VolitionRx waives Lind note covenant breach, triggers 10% step-up charge

Reuters
·
May 23

VolitionRX Earnings Call Balances Breakthroughs and Risks

TIPRANKS
·
May 20

VolitionRX Earnings Call: Breakthrough Science, Cash Burn Risk

TIPRANKS
·
May 16

VolitionRx director Mickie Henshall steps down, won’t seek re-election

Reuters
·
May 16

VolitionRx publishes corporate deck outlining Nu.Q licensing strategy in cancer, sepsis diagnostics

Reuters
·
May 15

BRIEF-VolitionRX Limited Announces First Quarter 2026 Financial Results

Reuters
·
May 15

VolitionRX Q1 EPS $(0.97) Misses $(0.75) Estimate, Sales $985.076K Beat $426.600K Estimate

Benzinga Earnings
·
May 15

VolitionRX Q1 FY26 net loss widens 22% to $6.7 million; revenue more than doubles to $1 million

Reuters
·
May 15

VolitionRx schedules first-quarter earnings conference call and business update

Reuters
·
May 11

Press Release: VolitionRx Limited Schedules First Quarter 2026 Earnings Conference Call and Business Update

Dow Jones
·
May 11

VolitionRx feline cancer blood test study shows 86% sensitivity at 97% specificity

Reuters
·
May 06

VolitionRX Announces Submission of Manuscript for Nu.q® Vet Cancer Test in Cats

THOMSON REUTERS
·
May 06

VolitionRx detects nucleosomes in sepsis patients using finger-prick lateral flow prototype study

Reuters
·
Apr 29

VolitionRx enacts 1-for-20 reverse stock split via charter amendment

Reuters
·
Apr 29

VolitionRx wins NYSE American approval of compliance plan, avoids immediate delisting

Reuters
·
Apr 23

VolitionRX Announces Acceptance of Compliance Plan by Nyse American

THOMSON REUTERS
·
Apr 23

VolitionRX Cut to Hold From Buy by D. Boral Capital

Dow Jones
·
Apr 20

VolitionRx downgraded to Hold from Buy at D. Boral Capital

TIPRANKS
·
Apr 20